Basic Information
| LncRNA/CircRNA Name | CANT1 |
| Synonyms | CANT1, DBQD, DBQD1, SCAN-1, SCAN1, SHAPY |
| Region | GRCh38_17:78991717-79009867 |
| Ensemble | ENSG00000171302 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | retinoblastoma |
| ICD-0-3 | C69.2 |
| Methods | qPCR, Western blot etc. |
| Sample | retinoblastoma tissues and paired normal tissues, cell lines (293T) |
| Expression Pattern | down-regulated |
| Function Description | CANT1 modulation mechanism and provide an alternative option for the RB treatment.lncRNA CASC15-New-Transcript 1 (CANT1) was significantly downregulated in RB. |
| Pubmed ID | 32366932 |
| Year | 2020 |
| Title | LncRNA CANT1 suppresses retinoblastoma progression by repellinghistone methyltransferase in PI3K? promoter. |
External Links
| Links for CANT1 | GenBank HGNC NONCODE |
| Links for retinoblastoma | OMIM COSMIC |